EAACI Congress 2024

31 May - 03 June 2024 Valencia, Spain

TPS18 - Biologicals 1

Friday 31 May, 12:00 PM - 13:00 PM Valencia, Spain
Poster Zone Thematic Poster Session
12 months retrospective real-life study on the clinical course of CRSwNP and respiratory function in patients with EGPA treated with biological drugs
A Case of EGPA Treated with Mepolizumab
Baseline Characteristics of Patients with Severe Asthma in Spain according to biological treatment use: BREATHE study
Baseline disease burden in severe asthma patients treated with biologics, and eligible but not treated: Spanish patients in the ISAR Registry
Budget impact of omalizumab biosimilar from the French healthcare perspective
Dupilumab in type 2 inflammatory diseases: a pediatric clinical case
Efficacy and injection schedule adjustment of Dupilumab in patients with chronic rhinosinusitis: Recent experiences in SNUH
Eosinophilia over dupilumab treatment in asthma patients: a multicentric retrospective study
Evaluation of Early Real-World Efficacy and Safety of Mepolizumab in Chronic Rhinosinusitis with Nasal Polyposis Through a Multidisciplinary Approach
Flow cytometry analysis of peripheral blood CRTH2+ cell subpopulations of dupilumab-treated patients
Longitudinal Assessment of Dupilumab's Therapeutic Effects in Chronic Rhinosinusitis with Nasal Polyps
MY010: anti-allergen antibodies for the treatment of Fagales pollen allergy
Mepolizumab Efficacy in Eosinophilic Granulomatosis with Polyangiitis with intractable middle ear effusion: a Case Report
Real-Life Effectiveness of Mepolizumab and Omalizumab in Sever Uncontrolled Chronic Rhinosinusitis with Nasal Polyps: A Prospective Study
The Effects of dupilumab in patients with chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery